초록 ▼

The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or l

The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

대표청구항 ▼

What is claimed is: 1. A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof wherein: X is selected from CR11, and N; Y is selected from CR12, and N; R3 and R

What is claimed is: 1. A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof wherein: X is selected from CR11, and N; Y is selected from CR12, and N; R3 and R8 are each hydroxyl; R11 and R12 are each independently selected from alkoxy, aryloxy, alkenyl, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone; R1, R5, R6, and R10 are each independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone; R2, R4, R7, and R9, are each independently selected from aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone, or two adjacent substituents selected from R1, R2, R4, R5, R6, R7, R9, R10, R11, and R12 are connected in a 5 or 6-membered ring to form a bicyclic aryl or bicyclic heteroaryl; each W is independently selected from C and N; and Z is a double bond; provided that: R2 and R4 are not each hydroxyl; at least one W is N; when W is N, then p is 0; and when W is C, then p is 1 2. The method of claim 1, wherein the therapeutically effective amount of the compound of Formula I is sufficient to establish a concentration ranging from about 0.001 μM to about 100 μM in the mammal. 3. The method of claim 2, wherein the concentration ranges from about 1 μM to about 20 μM. 4. The method of claim 1, wherein the therapeutically effective amount of the compound of Formula I is administered with a pharmaceutically acceptable carrier in a pharmaceutically acceptable composition. 5. The method of claim 1, further comprising treating or reducing the risk of developing a cardiovascular, cholesterol or lipid related disorder. 6. The method of claim 1, wherein the double bond is an E-double bond. 7. A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound selected from: 4,4′-dihydroxy-stilbene; 6-[(E)-2-(4-Hydroxy-phenyl)-vinyl]-pyridin-3-ol; 5-[(E)-2-(4-Hydroxy-phenyl)-vinyl]-pyrazin-2-ol; 5-{[1-(4-Hydroxy-phenyl)-meth-(E)-ylidene]-amino}-pyridin-2-ol; 5-(4-Hydroxy-phenylazo)-pyridin-2-ol; 3-Hydroxymethyl-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-phenol; 2-Hydroxy-5-[(E)-2-(4-hydroxyphenyl)vinyl]benzoic acid; 3-Nitro-4-[(E)-2-(4-hydroxyphenyl)-vinyl]phenol; (E)-Ethyl 2-hydroxy-5-(4-hydroxystyryl) benzoate; 4-[(E)-2-(4-Hydroxyphenyl)vinyl]-3-methanesulfonylphenol; 3-Amino-4-[(E)-2-(4-hydroxy-phenyl)vinyl]phenol; N-{5-Hydroxy-2-[(E)-2-(4-hydroxyphenyl)vinyl]phenyl}-acetamide; 5-Hydroxy-2-[2-(4-hydroxyphenyl)vinyl]-N,N-dimethylbenzamide; 4-[4-Hydroxy-phenethyl]-phenol; 4-Hydroxy-thiobenzoic acid S-(4-hydroxy-phenyl) ester; 4-Hydroxy-benzoic acid pyridin-2-yl ester; 4-(4-Hydroxy-phenyl)-azophenol, and pharmaceutically acceptable salts thereof. 8. A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of 5-[(E)-2-(4-Hydroxyphenyl)-vinyl]-pyridin-2-ol, or a pharmaceutically acceptable salt thereof. 9. The method according to claim 5, wherein the cardiovascular, cholesterol or lipid related disorder is selected from acute coronary syndrome, angina pectoris, arteriosclerosis, atherosclerosis, carotid atherosclerosis, cerebrovascular disease, cerebral infarction, congestive heart failure, congenital heart disease, coronary heart disease, coronary artery disease, coronary plaque stabilization, dyslipidemias, dyslipoproteinemias, endothelium dysfunctions, familial hypercholeasterolemia, familial combined hyperlipidemia, hypertension, hyperlipidemia, intermittent claudication, ischemia, ischemia reperfusion injury, ischemic heart diseases, multi-infarct dementia, myocardial infarction, peripheral vascular disease, restenosis, renal artery atherosclerosis, rheumatic heart disease, stroke, thrombotic disorder, transitory ischemic attacks, and lipoprotein abnormalities associated with Alzheimer's disease, obesity, diabetes mellitus, syndrome X and impotence. 10. The method according to claim 9, wherein the cardiovascular, cholesterol or lipid related disorder is selected from dyslipidemias, dyslipoproteinemias, hypertension, coronary artery disease, and atherosclerosis. 11. The method of claim 1, wherein R1, R5, R6, and R10 are each independently selected from alkoxy, aryloxy, alkyl, amide, amino, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, hydrogen, hydroxyl, nitro, phosphate, sulfonyl, sulfonic acid, and sulfonamide. 12. The method of claim 1, wherein R2, R4, R7, and R9, are each independently selected from amide, amino, carboxy, cyano, ester, ether, formyl, halogen, hydrogen, hydroxyl, phosphate, sulfide, sulfonic acid, and sulfonamide. 13. The method of claim 1, wherein only one W is N.